Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease.

Academic Article

Abstract

  • BACKGROUND: National guidelines recommend use of high-intensity statins after hospitalization for coronary heart disease (CHD) events. OBJECTIVES: This study sought to estimate the proportion of Medicare beneficiaries filling prescriptions for high-intensity statins after hospital discharge for a CHD event and to analyze whether statin intensity before hospitalization is associated with statin intensity after discharge. METHODS: We conducted a retrospective cohort study using a 5% random sample of Medicare beneficiaries between 65 and 74 years old. Beneficiaries were included in the analysis if they filled a statin prescription after a CHD event (myocardial infarction or coronary revascularization) in 2007, 2008, or 2009. High-intensity statins included atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, and simvastatin 80 mg. RESULTS: Among 8,762 Medicare beneficiaries filling a statin prescription after a CHD event, 27% of first post-discharge fills were for a high-intensity statin. The percent filling a high-intensity statin post-discharge was 23.1%, 9.4%, and 80.7%, for beneficiaries not taking statins pre-hospitalization, taking low/moderate-intensity statins, and taking high-intensity statins before their CHD event, respectively. Compared with beneficiaries not on statin therapy pre-hospitalization, multivariable adjusted risk ratios for filling a high-intensity statin were 4.01 (3.58-4.49) and 0.45 (0.40-0.52) for participants taking high-intensity and low/moderate-intensity statins before their CHD event, respectively. Only 11.5% of beneficiaries whose first post-discharge statin fill was for a low/moderate-intensity statin filled a high-intensity statin within 365 days of discharge. CONCLUSIONS: The majority of Medicare beneficiaries do not fill high-intensity statins after hospitalization for CHD.
  • Keywords

  • coronary artery disease, drug use, hydroxymethylglutaryl-CoA reductase inhibitors, secondary prevention, Aged, Cohort Studies, Coronary Artery Bypass, Coronary Disease, Dose-Response Relationship, Drug, Drug Prescriptions, Female, Hospitalization, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Medicare, Myocardial Infarction, Patient Discharge, Percutaneous Coronary Intervention, Retrospective Studies, Secondary Prevention, United States
  • Digital Object Identifier (doi)

    Pubmed Id

  • 8094269
  • Authorlist

  • Rosenson RS; Kent ST; Brown TM; Farkouh ME; Levitan EB; Yun H; Sharma P; Safford MM; Kilgore M; Muntner P
  • Start Page

  • 270
  • End Page

  • 277
  • Volume

  • 65
  • Issue

  • 3